Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.

Invasive Breast Cancer

Chemotherapeutic Toxicity

Myalgia

Arthralgia

Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion

Gabapentin 300mg

Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy

Primary Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy: A Randomized Controlled Trial

Brief Pain Inventory-short form assessment tool

British Columbia Cancer Agency

Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment

Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment

Alcohol Dependence

Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.
All patients will receive standard of care treatment.

Gabapentin 2g/day divided in two doses for 24 weeks

Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.

Placebo 2g/day divided in two doses for 24 weeks

Dyanand Medical College and Hospital

Treatment for Alcohol Dependence With Gabapentin

Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial

(Pattern of reduced drinking, described as no heavy episodic drinking. Heavy episodic drinking days are defined by the FDA - National Institute on Alcohol Abuse and Alcoholism (NIAAA) as days when the patient consumes more than four standard drinks (men) or more than three standard drinks (women). Responder analysis will be applied to the rate of Heavy Episodic Drinking.

Drinking urges were assessed by self-report using the Alcohol Craving Questionnaire-Short Form.

Mood was evaluated by self report with the Beck Depression Inventory II

Multiple components of sleep disturbance were assessed by self-report using the Pittsburgh Sleep Quality Index

butyric acid/neoplasms

Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy

Treatment for Alcohol Dependence With Gabapentin

The most complete medicinal herbs database backed by science